|
|
Blood, 1 April 2004, Vol. 103, No. 7, pp. 2571-2576.
Prepublished online as a Blood First Edition Paper on November 13, 2003; DOI 10.1182/blood-2003-07-2316.
Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Severe hypodysfibrinogenemia in compound heterozygotes of the fibrinogen A IVS4 + 1G>T mutation and an A Gln328 truncation (fibrinogen Keokuk)
Phil Lefebvre,
Pauline T. Velasco,
Amy Dear,
Karim C. Lounes,
Susan T. Lord,
Stephen O. Brennan,
David Green, and
Laszlo Lorand
From the Department of Cell and Molecular Biology and the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL; the Molecular Pathology Laboratory, Canterbury Health Laboratories, Christchurch, New Zealand; and the Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill.
Two siblings with hypofibrinogenemia have lifelong trauma-related bleeding. Recently, the brother experienced recurrent thrombosis after cryoprecipitate infusions following surgery. The sister had 6 miscarriages. Plasma clots in each were resistant to compression and fibrinolysis and were soluble in 5 M urea. Examination by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) revealed only the presence of crosslinked fibrin chain dimers without high polymers of n. Fibrin clots contained an abnormal 35-kDa constituent recognized by an antibody to the mature fibrinogen A chain residues 241-476 but not by antibodies to A 219-348 or A 349-406. DNA analysis revealed a heterozygous CAA TAA mutation at the codon for amino acid 328 of the A gene in these siblings and 2 asymptomatic family members. The Gln328stop mutation (fibrinogen Keokuk) predicted a 46% truncation and the production of a 35-kDa A chain. Analysis of purified fibrinogen revealed expression of the abnormal A chain in 4 family members but found no normal fibrinogen in the 2 hypofibrinogenemic patients. This paradox was resolved when they and their asymptomatic mother were found to be heterozygous for a second A mutation, a GT TT splice site mutation in intron 4 (IVS4 + 1 G> T). However, compound heterozygosity for both mutations was required for the expression of severe hypodysfibrinogenemia and for clinical symptoms.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Uitte de Willige, K. F. Standeven, H. Philippou, and R. A. S. Ariens
The pleiotropic role of the fibrinogen {gamma}' chain in hemostasis
Blood,
November 5, 2009;
114(19):
3994 - 4001.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. O. Brennan, R. L. Davis, R. Lowen, and A. Ruskova
Deletion of five residues from the coiled coil of fibrinogen (B{beta} Asn167_Glu171del) associated with bleeding and hypodysfibrinogenemia
Haematologica,
April 1, 2009;
94(4):
585 - 588.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Lorand
Crosslinks in blood: transglutaminase and beyond
FASEB J,
June 1, 2007;
21(8):
1627 - 1632.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Park, H.-J. Doh, S.-S. A. An, J.-R. Choi, K.-H. Chung, and K.-S. Song
A novel fibrinogen variant (fibrinogen Seoul II; A{alpha}Gln328Pro) characterized by impaired fibrin {alpha}-chain cross-linking
Blood,
September 15, 2006;
108(6):
1919 - 1924.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. S. Song, N. J. Park, J. R. Choi, H. J. Doh, and K. H. Chung
Fibrinogen Seoul (FGG Ala341Asp): A Novel Mutation Associated With Hypodysfibrinogenemia
Clinical and Applied Thrombosis/Hemostasis,
July 1, 2006;
12(3):
338 - 343.
[Abstract]
[PDF]
|
 |
|
|
|